Key facts
- Ikarovec’s last known valuation is $184.0M.
- It has raised $43.9M; the latest was Later Stage VC ($46.0M) in Oct 2025.
- Notable investors include Future Planet Capital, Parkwalk Advisors, Cambridge Enterprise Ventures, UK Innovation & Science Seed Fund, BioIndustry Association — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Ikarovec
- ·The full record, as it builds
Funding rounds
No funding rounds for Ikarovec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ikarovec
Operator of a gene therapy company intended to treat common eye diseases. The company targets multiple disease targets and pathways that help in targeting multiple disease targets and pathways treatment for diabetic macular edema, dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension, enabling patients to get the required treatment for restoring sight and preventing blindness.
- Sector
- Healthcare
- HQ
- Norwich, United Kingdom
- Founded
- 2018
- Employees
- 8
- Website
- ikarovec.com/
- Ownership
- Privately Held (backing)
Ikarovec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ikarovec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ikarovec in its N-PORT filings yet. We sweep new filings monthly.